Affiliated Psychological Hospital of Anhui Medical University, Hefei, China.
Department of Pharmacy, Hefei Fourth People's Hospital, Hefei, China.
BMC Psychiatry. 2024 Jun 14;24(1):449. doi: 10.1186/s12888-024-05910-0.
Accumulating evidence supports the idea that inflammation may contribute to the pathophysiology of major depressive disorder (MDD). Duloxetine, a serotonin-norepinephrine reuptake inhibitor, exhibits anti-inflammatory effects both in vitro and in vivo. In this study, we investigated the impact of duloxetine on changes in serum proinflammatory cytokine levels among individuals diagnosed with MDD.
A cohort of 23 drug-naïve individuals diagnosed with MDD and 23 healthy controls were included in this study. The severity of depressive symptoms was evaluated using the 24-item Hamilton Depression Scale (HAMD-24). A panel of 7 proinflammatory cytokines, including interleukin-1β (IL-1β), IL-2, IL-6, IL-8, IL-12, tumor necrosis factor-α (TNF-α), and interferon-γ (IFN-γ), were quantified using multiplex Luminex assays. The levels of serum cytokines in healthy controls and patients with MDD were compared at baseline. All patients received duloxetine at a dosage range of 40-60 mg/day for a duration of 4 weeks. The HAMD-24 scores and serum cytokine levels were compared before and after duloxetine treatment.
Compared with healthy controls, patients with MDD had significantly greater levels of IL-2, IL-6, IL-8, IL-12, TNF-α, and IFN-γ (P < 0.05). Moreover, there was a significant decrease in HAMD-24 scores observed pre- and post-treatment (t = 13.161, P < 0.001). Furthermore, after 4 weeks of treatment, the serum levels of IL-8 (t = 3.605, P = 0.002), IL-12 (t = 2.559, P = 0.018), and IFN-γ (t = 3.567, P = 0.002) decreased significantly. However, there were no significant differences in other cytokines, including IL-1β, IL-2, IL-6, and TNF-α, before and after treatment (P > 0.05).
These findings present compelling evidence, potentially for the first time, indicating that duloxetine treatment may effectively reduce the serum concentrations of IL-8, IL-12, and IFN-γ in individuals diagnosed with MDD. However, the precise mechanisms underlying this effect remain unclear and warrant further investigation.
越来越多的证据支持炎症可能导致重度抑郁症(MDD)的病理生理学这一观点。度洛西汀是一种 5-羟色胺和去甲肾上腺素再摄取抑制剂,在体外和体内均具有抗炎作用。本研究旨在探讨度洛西汀对 MDD 患者血清前炎性细胞因子水平变化的影响。
本研究纳入了 23 名未经药物治疗的 MDD 患者和 23 名健康对照者。采用 24 项汉密尔顿抑郁量表(HAMD-24)评估抑郁症状严重程度。采用多重 Luminex 检测法检测白细胞介素-1β(IL-1β)、IL-2、IL-6、IL-8、IL-12、肿瘤坏死因子-α(TNF-α)和干扰素-γ(IFN-γ)等 7 种前炎性细胞因子的水平。比较健康对照组和 MDD 患者的基线血清细胞因子水平。所有患者均接受度洛西汀治疗,剂量范围为 40-60mg/天,疗程 4 周。比较度洛西汀治疗前后 HAMD-24 评分和血清细胞因子水平。
与健康对照组相比,MDD 患者的 IL-2、IL-6、IL-8、IL-12、TNF-α和 IFN-γ水平显著升高(P<0.05)。此外,治疗前后 HAMD-24 评分均显著降低(t=13.161,P<0.001)。进一步分析发现,治疗 4 周后,血清 IL-8(t=3.605,P=0.002)、IL-12(t=2.559,P=0.018)和 IFN-γ(t=3.567,P=0.002)水平显著降低。然而,治疗前后其他细胞因子(包括 IL-1β、IL-2、IL-6 和 TNF-α)水平无显著差异(P>0.05)。
这些发现首次提供了令人信服的证据,表明度洛西汀治疗可能有效降低 MDD 患者血清中 IL-8、IL-12 和 IFN-γ的浓度。然而,其确切机制尚不清楚,需要进一步研究。